Making rareness count: testing and pricing orphan drugs

Abstract : This paper examines the testing and the pricing of orphan drugs, e.g. drugs for patients suffering from rare diseases. Due to the small size of these populations, orphan molecules question established evidentiary practices, namely randomized controlled trials (RCT) and health technology assessments (HTA), driven by numbers and statistical reasoning. Drawing on the notions of “statactivism” (Bruno et al. 2014) and “evidence-based activism” (Rabeharisoa et al. 2014), this paper shows how stakeholders in the field of rare diseases come to test a variety of solutions, ranging from adapting RCT and HTA on the fringe, advocating for exceptional procedures, to recomposing RCT and HTA from within. These initiatives offer new insights into the pricing of orphan drugs as a testing device of who is accountable for the evaluation of these molecules, and of how rare diseases are made to count for society at large.
Type de document :
Autre publication
Liste complète des métadonnées

Littérature citée [16 références]  Voir  Masquer  Télécharger

https://hal-mines-paristech.archives-ouvertes.fr/hal-01379153
Contributeur : Catherine Lucas <>
Soumis le : mercredi 12 octobre 2016 - 11:33:46
Dernière modification le : lundi 12 novembre 2018 - 11:02:03
Document(s) archivé(s) le : vendredi 13 janvier 2017 - 12:21:37

Fichier

WPi3_16-CSI-03_Rabeharisoa & D...
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : hal-01379153, version 1

Citation

Vololona Rabeharisoa, Liliana Doganova. Making rareness count: testing and pricing orphan drugs. 2016. ⟨hal-01379153⟩

Partager

Métriques

Consultations de la notice

211

Téléchargements de fichiers

113